Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06471842
Recruiting Observational

Study of the Prevalence of Pediatric Eating Disorders in Inherited Metabolic Diseases With Dietary Treatment

NCT06471842 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2024-08-21
Last updated
2025-11-20

Condition(s) studied

Inherited Metabolism Disease

Investigational drug(s) / intervention(s)

MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire

MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire: The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.

Study summary

The main objective of this study is to estimate the prevalence of Pediatric Eating Disorders (PED) in Inherited Metabolic Diseases (IMD) with dietary treatment between the age of 12 months and 6 years 11 months.

Eligibility

Sex
ALL
Min age
12 Months
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria: * Patient from 12 months to 6 years and 11 months old * Patient with an Inherited Metabolic Diseases with dietary treatment * Patient having experimented a dietary diversification at least 6 month prior * Patient whose parents do not object to their participation in the study Exclusion Criteria: * Patient with an associated chronic disease * Patient with diagnosed Autistic Spectrum Disorder (ASD) or Pervasive Developmental Disorders (PDD) * Patient born before 36 weeks of amenorrhea * Patient with multiple disabilities * Patient with dystonia * Patient with absent or unstable head posture * Patient whose parents do not fully understand or speak French

Primary outcome measure(s)

  • Feeding scale score — 1 day
    MCH (Montreal Children's Hospital) feeding scale score between the age of 12 months and 6 years 11 months.

Trial sites (1)

FacilityCityRegionStatus
Necker Enfants Malades Hospital Paris France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Fusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions Active, not recruiting
neonAtal motoR paTtErn autoMatIc analySis Recruiting
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis Recruiting
Effect of Adding Vasopressin on Cardiac Output, Blood Pressure, Diuresis, and Tissue Perfusion Indices in Patients With Septic Shock Starting soon
Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06471842 on ClinicalTrials.gov ↗ ← All trials in France